JP2017533706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533706A5 JP2017533706A5 JP2017523266A JP2017523266A JP2017533706A5 JP 2017533706 A5 JP2017533706 A5 JP 2017533706A5 JP 2017523266 A JP2017523266 A JP 2017523266A JP 2017523266 A JP2017523266 A JP 2017523266A JP 2017533706 A5 JP2017533706 A5 JP 2017533706A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- tcr
- cells
- nucleic acid
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021084334A JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2025169833A JP2025188145A (ja) | 2014-10-31 | 2025-10-08 | 改変ｔ細胞に関する方法および組成物 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073540P | 2014-10-31 | 2014-10-31 | |
| US201462073144P | 2014-10-31 | 2014-10-31 | |
| US201462073467P | 2014-10-31 | 2014-10-31 | |
| US201462073343P | 2014-10-31 | 2014-10-31 | |
| US201462073681P | 2014-10-31 | 2014-10-31 | |
| US62/073,343 | 2014-10-31 | ||
| US62/073,540 | 2014-10-31 | ||
| US62/073,681 | 2014-10-31 | ||
| US62/073,467 | 2014-10-31 | ||
| US62/073,144 | 2014-10-31 | ||
| PCT/US2015/058339 WO2016070061A1 (en) | 2014-10-31 | 2015-10-30 | Methods and compositions for modified t cells |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021084334A Division JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A Division JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533706A JP2017533706A (ja) | 2017-11-16 |
| JP2017533706A5 true JP2017533706A5 (enExample) | 2023-06-08 |
| JP7372728B2 JP7372728B2 (ja) | 2023-11-01 |
Family
ID=55858404
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523266A Active JP7372728B2 (ja) | 2014-10-31 | 2015-10-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2021084334A Withdrawn JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A Active JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2025169833A Pending JP2025188145A (ja) | 2014-10-31 | 2025-10-08 | 改変ｔ細胞に関する方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021084334A Withdrawn JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A Active JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2025169833A Pending JP2025188145A (ja) | 2014-10-31 | 2025-10-08 | 改変ｔ細胞に関する方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170258835A1 (enExample) |
| EP (2) | EP4653013A3 (enExample) |
| JP (4) | JP7372728B2 (enExample) |
| KR (1) | KR20170074243A (enExample) |
| CN (1) | CN107106670A (enExample) |
| AU (1) | AU2015338984A1 (enExample) |
| CA (1) | CA2964958A1 (enExample) |
| ES (1) | ES3061201T3 (enExample) |
| HK (1) | HK1243333A1 (enExample) |
| PL (1) | PL3212225T3 (enExample) |
| PT (1) | PT3212225T (enExample) |
| SI (1) | SI3212225T1 (enExample) |
| WO (1) | WO2016070061A1 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2017004252A1 (en) | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
| US12577289B2 (en) | 2015-06-30 | 2026-03-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Surrogate co-receptors for t cells and methods of use |
| WO2017040324A1 (en) * | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| WO2017040195A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| JP7054924B2 (ja) | 2015-09-23 | 2022-04-15 | サイトイミューン セラピューティクス， インコーポレイテッド | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| CA3005878A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
| CN109072194B (zh) * | 2015-12-09 | 2022-12-27 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物及其使用方法 |
| US11576932B2 (en) * | 2016-03-31 | 2023-02-14 | Lion Tcr Pte. Ltd. | Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR) |
| WO2017177337A1 (en) * | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| CN107522786A (zh) * | 2016-06-20 | 2017-12-29 | 深圳市体内生物医药科技有限公司 | 一种分子、表达其的细胞及其制备方法和用途 |
| CN107586341A (zh) * | 2016-07-08 | 2018-01-16 | 生命序有限公司 | 重组免疫检查点受体及免疫检查点抑制分子的共表达及应用 |
| CN107586342A (zh) * | 2016-07-08 | 2018-01-16 | 生命序有限公司 | 重组免疫检查点受体及其应用 |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3034691A1 (en) | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| WO2018089386A1 (en) | 2016-11-11 | 2018-05-17 | The Broad Institute, Inc. | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| CN108264562B (zh) * | 2016-12-30 | 2021-08-10 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞正共刺激分子的双功能分子及其应用 |
| EP3575319A4 (en) * | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | BIFUNCTIONAL MOLECULE AND USE OF IT |
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| US12590288B2 (en) | 2017-04-12 | 2026-03-31 | The Broad Institute, Inc. | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response |
| EP4759318A2 (en) * | 2017-04-14 | 2026-06-17 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| CN110868853A (zh) * | 2017-04-26 | 2020-03-06 | 纪念斯隆-凯特琳癌症中心 | 即用型冷冻保存细胞 |
| US12226479B2 (en) | 2017-05-11 | 2025-02-18 | The General Hospital Corporation | Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| KR102379189B1 (ko) | 2017-06-13 | 2022-03-25 | 엘지디스플레이 주식회사 | 연성 표시 패널을 포함하는 롤러블 디스플레이 장치 |
| EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| CN111315403A (zh) * | 2017-09-15 | 2020-06-19 | 凯德药业股份有限公司 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
| JP7404230B2 (ja) * | 2017-09-18 | 2023-12-25 | トラスティーズ オブ ボストン ユニバーシティ | ネトーシスおよび好中球活性化を処置するための方法 |
| CN117843810A (zh) | 2017-09-22 | 2024-04-09 | 上海药明生物技术有限公司 | 新型双特异性多肽复合物 |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| US12171783B2 (en) | 2017-11-13 | 2024-12-24 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| CN111684061B (zh) * | 2018-01-19 | 2024-07-30 | 美天施生物科技有限两合公司 | 表达嵌合抗原受体的调节性t细胞 |
| US12492254B2 (en) | 2018-02-23 | 2025-12-09 | H. Lee Moffitt Cancer Center and Research Intitute. Inc. | CD83-binding chimeric antigen receptors |
| EP4495246A3 (en) | 2018-03-01 | 2025-03-26 | University of Kansas | Techniques for generating cell-based therapeutics using recombinant t cell receptor genes |
| WO2019178342A1 (en) * | 2018-03-15 | 2019-09-19 | Fundamental Solutions Corporation | Programmable immunocyte receptor complex system |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| WO2019222642A1 (en) * | 2018-05-18 | 2019-11-21 | Senti Biosciences, Inc. | Engineered immune cells and methods of use |
| WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2020033273A1 (en) * | 2018-08-04 | 2020-02-13 | AbCyte Therapeutics Inc. | Multi-function and multi-targeting car system and methods for use thereof |
| CN112805369A (zh) * | 2018-08-08 | 2021-05-14 | 南特生物公司 | 重组cd1限制性t细胞及方法 |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| CN109722437B (zh) * | 2018-12-29 | 2020-01-07 | 广州百暨基因科技有限公司 | 一种通用型car-t细胞及其制备方法和用途 |
| CN111378622B (zh) * | 2018-12-29 | 2022-12-02 | 华东师范大学 | 核酸编码的car-t细胞及其制备方法和应用 |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| EP3917969A4 (en) * | 2019-01-28 | 2023-02-01 | Wuxi Biologics Ireland Limited | NEW BISPECIFIC CD3/CD20 POLYPEPTIDIC COMPLEXES |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| CA3136626A1 (en) * | 2019-04-12 | 2020-10-15 | Emory University | Compositions and methods for promoting hematopoietic cell cytotoxicity |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| US12018081B1 (en) * | 2019-08-28 | 2024-06-25 | The Regents Of The University Of Colorado, A Body Corporate | Photoconjugation reactions for modification of specific proteins on live cells |
| US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| CN114729059A (zh) | 2019-09-11 | 2022-07-08 | 宾夕法尼亚大学董事会 | 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法 |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| JP2023522330A (ja) | 2020-04-17 | 2023-05-30 | シティ・オブ・ホープ | Ｆｌｔ３陽性悪性腫瘍を処置するためのｆｌｔ３標的化キメラ抗原受容体改変細胞 |
| CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| CN116635519A (zh) * | 2020-11-26 | 2023-08-22 | 上海医药集团生物治疗技术有限公司 | 一种经修饰的免疫细胞及其应用 |
| CN117295506A (zh) * | 2021-03-10 | 2023-12-26 | H·李·莫菲特癌症中心和研究所股份有限公司 | 降低治疗性t细胞毒性的组合物和方法 |
| US20240112754A1 (en) * | 2021-03-12 | 2024-04-04 | Adaptive Biotechnologies Corporation | Crohn's Disease-Associated T Cell Receptor-Related Methods |
| EP4310188A1 (en) | 2021-03-17 | 2024-01-24 | Daiichi Sankyo Company, Limited | Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody |
| CN115505572B (zh) * | 2021-06-22 | 2025-11-14 | 康立泰生物医药(青岛)有限公司 | 一种增强型抗肿瘤nk细胞及其制备方法和应用 |
| CN119546326A (zh) * | 2022-06-06 | 2025-02-28 | 卡里布生物科学公司 | 用经工程化的免疫细胞治疗自身免疫性疾病 |
| CN116083369B (zh) * | 2022-09-01 | 2025-05-09 | 华中科技大学同济医学院附属同济医院 | 双特异性抗体修饰囊泡、双特异性抗体、核酸、重组载体、基因工程细胞、方法和应用 |
| EP4598949A1 (en) | 2022-10-07 | 2025-08-13 | The General Hospital Corporation | Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025064482A2 (en) * | 2023-09-19 | 2025-03-27 | Ginkgo Bioworks, Inc. | Chimeric immune cell receptors |
| CN117106035B (zh) * | 2023-10-25 | 2024-04-23 | 烟台药物研究所 | 一种肿瘤靶向多肽、多肽偶联药物及制备与应用 |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA120409A (en) | 1909-05-13 | 1909-09-07 | Hiram Lucas Piper | Signal lamp |
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US6080840A (en) | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| DE69433970T2 (de) | 1993-08-10 | 2005-08-11 | W.L. Gore & Associates, Inc., Newark | Zelleinkapselungsvorrichtung |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JPH10503964A (ja) | 1995-06-07 | 1998-04-14 | ゴア ハイブリッド テクノロジーズ，インコーポレイティド | 治療用デバイスのための移植可能な閉じ込め装置並びにその中にそのデバイスを装填及び再装填する方法 |
| US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| AU6854696A (en) | 1995-09-22 | 1997-04-09 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| WO2001066149A2 (en) | 2000-03-03 | 2001-09-13 | Valentis, Inc. | Nucleic acid formulations for gene delivery and methods of use |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| EP1188825A1 (en) * | 2000-09-18 | 2002-03-20 | Universiteit Leiden | T cell receptor transfer into a candidate effector cell or a precursor thereof |
| DE10109854A1 (de) | 2001-03-01 | 2002-09-12 | Thomas Stanislawski | Polypeptide eines hdm2-Protein spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| AU2003233197A1 (en) * | 2002-04-29 | 2003-11-17 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
| DE10244457A1 (de) * | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| US8642743B2 (en) | 2004-04-06 | 2014-02-04 | Affibody Ab | Method for reducing the immune response to a biologically active protein |
| EP1611850A1 (fr) * | 2004-06-28 | 2006-01-04 | Cardio Life Research S.A. | Dispositif d'occlusion et de ponction étanche pour structure anatomique. |
| CN101072880A (zh) * | 2004-07-01 | 2007-11-14 | VIRxSYS股份有限公司 | 载体包装细胞系 |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| CN101370927A (zh) | 2005-12-07 | 2009-02-18 | 基因特伦尼克斯公司 | 可变容积电穿孔室以及其方法 |
| US8426557B2 (en) | 2007-08-03 | 2013-04-23 | Affibody Ab | IGF-1R binding polypeptides and their use |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| JP2012507299A (ja) | 2008-10-31 | 2012-03-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｌｉｇｈｔ標的分子およびその使用 |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US9211321B2 (en) * | 2009-10-27 | 2015-12-15 | Immunicum Ab | Method for proliferation of antigen-specific T cells |
| CN102812043A (zh) * | 2009-11-19 | 2012-12-05 | 新加坡国立大学 | 用于制备t细胞受体样单克隆抗体的方法及其用途 |
| US9345748B2 (en) * | 2010-09-21 | 2016-05-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SSX-2 T cell receptors and related materials and methods of use |
| CA2816379A1 (en) * | 2010-10-27 | 2012-05-03 | Baylor College Of Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| MX2014001222A (es) * | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| JP5737082B2 (ja) | 2011-08-31 | 2015-06-17 | 富士通株式会社 | ポインタ位置補正方法、ポインタ位置補正プログラムおよびサーバ装置 |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| KR20150029714A (ko) * | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| US20160015749A1 (en) * | 2013-03-05 | 2016-01-21 | Baylor College Of Medicine | Engager cells for immunotherapy |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
-
2015
- 2015-10-30 PL PL15855013.7T patent/PL3212225T3/pl unknown
- 2015-10-30 EP EP25207728.4A patent/EP4653013A3/en active Pending
- 2015-10-30 KR KR1020177014658A patent/KR20170074243A/ko not_active Withdrawn
- 2015-10-30 PT PT158550137T patent/PT3212225T/pt unknown
- 2015-10-30 SI SI201532095T patent/SI3212225T1/sl unknown
- 2015-10-30 AU AU2015338984A patent/AU2015338984A1/en not_active Abandoned
- 2015-10-30 WO PCT/US2015/058339 patent/WO2016070061A1/en not_active Ceased
- 2015-10-30 US US15/518,922 patent/US20170258835A1/en active Pending
- 2015-10-30 JP JP2017523266A patent/JP7372728B2/ja active Active
- 2015-10-30 CN CN201580071613.7A patent/CN107106670A/zh active Pending
- 2015-10-30 ES ES15855013T patent/ES3061201T3/es active Active
- 2015-10-30 HK HK18102826.6A patent/HK1243333A1/zh unknown
- 2015-10-30 CA CA2964958A patent/CA2964958A1/en not_active Abandoned
- 2015-10-30 EP EP15855013.7A patent/EP3212225B1/en active Active
-
2021
- 2021-05-19 JP JP2021084334A patent/JP2021121208A/ja not_active Withdrawn
-
2023
- 2023-05-30 JP JP2023088510A patent/JP7757343B2/ja active Active
-
2025
- 2025-10-08 JP JP2025169833A patent/JP2025188145A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside | |
| Rezvani et al. | Engineering natural killer cells for cancer immunotherapy | |
| JP2017535261A5 (enExample) | ||
| Daher et al. | CAR‐NK cells: the next wave of cellular therapy for cancer | |
| JP2021058196A5 (enExample) | ||
| Shimasaki et al. | Expanded and armed natural killer cells for cancer treatment | |
| Du et al. | Therapeutic potential of natural killer cells in gastric cancer | |
| JP2017533707A5 (enExample) | ||
| JP7270253B2 (ja) | ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株 | |
| Wang et al. | Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges | |
| JP6022667B2 (ja) | 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ | |
| CN102597223B (zh) | 生产天然杀伤细胞的方法 | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2018504910A5 (enExample) | ||
| ES2910227T3 (es) | Composición y métodos para la estimulación y expansión de células T | |
| JP2018533625A5 (enExample) | ||
| CN105848484A (zh) | 用于免疫治疗的多克隆γδ T细胞 | |
| JP2019500894A5 (enExample) | ||
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| BR112020018670A2 (pt) | Receptor de antígeno quimérico de receptor alfa 2 da il-13 (il13ra2) para imunoterapia com células t específicas para tumor | |
| US20160237407A1 (en) | Universal donor chimeric antigen receptor cells | |
| JP7680032B2 (ja) | Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用 | |
| Kintz et al. | Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma | |
| Song et al. | Targeting cytokine signals to enhance γδT cell-based cancer immunotherapy | |
| JP2022512538A5 (enExample) |